Table 3. VTE risk by condition type and... | American Society of Hematology

Table 3.

VTE risk by condition type and COC use

Condition type	Baseline VTE incidence (95% CI)	RR with COC (95% CI)^a	Absolute risk with COC (95% CI)
Low-risk thrombophilia
Heterozygous FVL	0.5% (0.1-1.3%)/y⁵⁰ By age 45: 12%⁶⁴	RR 5.89 (4.21-8.23)⁴⁵	0.49 (0.18-1.07) to 2.0 (0.07-0.41) per 100 pill-years⁴⁵
Heterozygous PGM	0.4% (0.1-1.1%)/y	RR 5.24 (2.69-10.20)⁴⁵	0.49 (0.18-1.07) to 2.0 (0.07-0.41) per 100 pill-years⁴⁵
High-risk thrombophilia
Homozygosity of FVL or PGM or double heterozygosity^b	FVL: 1.8% (0.1-4.0%)/y⁵⁰	RR 7.15 (2.93-17.45)⁴⁵	0.86 (0.10-3.11) per 100 pill-years⁴⁵
AT, PC, or PS deficiency	1.5% (0.7-2.8%)/y⁵⁰ By age 45: AT: 41%, PC: 26%, PS: 21%⁶⁴	RR 7.15 (2.93-17.45)⁴⁵	4.3 (1.4-9.7) to 4.62 (2.5-7.9) per 100 pill-years⁴⁵
Antiphospholipid antibodies	Overall: 0.8-1.02 per 100 PY⁶⁵^,⁶⁶ LAC: 1.3% per year; 5.9% (1.2-10.6%) at 10 y⁶⁷ Triple positive^c: 9.8% at 2 y; 37.1% at 10 y⁶⁸	-	-
Sickle cell trait	Overall: 0.438 (0.324-0.720)/100 PY <70 y: 0.265 (0.139-0.469)/100 PY⁶⁹	OR 6.7 (1.0-43)⁶⁰	-
Sickle cell disease	3.58 (0.04-25.4)/100 PY⁶⁹; 11.3% (8.3-15.3%) by age 40⁷⁰	-	-

Condition type	Baseline VTE incidence (95% CI)	RR with COC (95% CI)^a	Absolute risk with COC (95% CI)
Low-risk thrombophilia
Heterozygous FVL	0.5% (0.1-1.3%)/y⁵⁰ By age 45: 12%⁶⁴	RR 5.89 (4.21-8.23)⁴⁵	0.49 (0.18-1.07) to 2.0 (0.07-0.41) per 100 pill-years⁴⁵
Heterozygous PGM	0.4% (0.1-1.1%)/y	RR 5.24 (2.69-10.20)⁴⁵	0.49 (0.18-1.07) to 2.0 (0.07-0.41) per 100 pill-years⁴⁵
High-risk thrombophilia
Homozygosity of FVL or PGM or double heterozygosity^b	FVL: 1.8% (0.1-4.0%)/y⁵⁰	RR 7.15 (2.93-17.45)⁴⁵	0.86 (0.10-3.11) per 100 pill-years⁴⁵
AT, PC, or PS deficiency	1.5% (0.7-2.8%)/y⁵⁰ By age 45: AT: 41%, PC: 26%, PS: 21%⁶⁴	RR 7.15 (2.93-17.45)⁴⁵	4.3 (1.4-9.7) to 4.62 (2.5-7.9) per 100 pill-years⁴⁵
Antiphospholipid antibodies	Overall: 0.8-1.02 per 100 PY⁶⁵^,⁶⁶ LAC: 1.3% per year; 5.9% (1.2-10.6%) at 10 y⁶⁷ Triple positive^c: 9.8% at 2 y; 37.1% at 10 y⁶⁸	-	-
Sickle cell trait	Overall: 0.438 (0.324-0.720)/100 PY <70 y: 0.265 (0.139-0.469)/100 PY⁶⁹	OR 6.7 (1.0-43)⁶⁰	-
Sickle cell disease	3.58 (0.04-25.4)/100 PY⁶⁹; 11.3% (8.3-15.3%) by age 40⁷⁰	-	-

RR estimates derived from case-control studies without a family history of VTE.

The majority of the data in this group comes from patients with homozygous FVL.

Triple positive: LAC, anticardiolipin antibody, and beta-2 glycoprotein antibody positivity.